亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Engineering Induced Pluripotent Stem Cells for COPD Therapy

总结
Researchers at Oklahoma State havedeveloped a method that can induce 90% differentiation of iPSCs or MSCs intoAECs (type II) under stimulation of proper growth factors and growing on anappropriate matrix. These cells expressed type II cell markers surfactantprotein C and ABCA3, secrete lung surfactant in response to lung surfactantsecretagogues and trans-differentiate into type I AECs. Inaddition, the researchers have demonstrated that the AEC cells attenuated lung injuryin a mouse model of COPD. The potential uses for these cells includecellular-based therapies, drug screening, disease modeling and pulmonary research.
技术优势
·        90% differentiation efficiency of iPSCs or MSCs into AECs
技术应用
·        Therapeutic for pulmonary diseases, including COPD·        Drug discovery·        Disease modeling·        Pulmonary research·        Stem cell research
详细技术说明
None
*Abstract
None
*Background
The discovery of mesenchymal stem cells(MSCs) and induced pluripotent stem cells (iPSCs) have resulted in a plethoraof opportunities to produce tissue-specific cell types for disease modeling, drugscreening and treatments for diseases. For pulmonary diseases such as COPD,stem cells have been a proposed strategy to repair damaged lungs. However, thesestudies have yielded controversial results. Additional research hasdemonstrated that transplantation of alveolar epithelial cells (AECs) holdgreat promise to repair damaged lungs for pulmonary diseases, including COPD.However, the conversion of stem cells to AECs has proven to be difficult withextremely low differentiation percentages. This major barrier has hamperedimplementation of AEC cells for use in therapies, disease modeling, drugscreening and other areas of pulmonary research. Given that over 300 milliondollars of NIH money is awarded each year to pulmonary researchers, and thatthe pulmonary drug and drug delivery market is estimated to reach 43.9 billiondollars by 2018, developing methods to efficiently produce AECs would bebeneficial.
*Stage of Development
These cells are developed and ready tobe used
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备